|
2015 Journal Article Nivolumab in Previously Untreated Melanoma without a BRAF mutationRobert, Caroline, Long, Georgina, Brady, Benjamin, Dutriaux, Caroline, Miao, Michele, Mortier, Laurent, Hassel, Jessica C., Rutkowski, Piotr, McNeil, Catriona, Kalinsk-Warzocha, Ewa, Savage, Kerry, Hernberg, Michaela, Lebbe, Cleste, Charles, Julie, Mihalcioiu, Caitlin, Chiarion-Sileni, Vanna, Mauch, Conrelia, Cognetti, Francesco, Arance, Ana, Schmidt, Kenrik, Schadendorf, Dirk, Gogas, Helen, Lundgren-Erikkson, Lotta, Horak, Christine, Sharkey, Brian, Waxman, Ian, Atkinson, Victoria and Ascierto, Paolo (2015). Nivolumab in Previously Untreated Melanoma without a BRAF mutation. The New England Journal of Medicine, 372 (4), 320-330. doi: 10.1056/NEJMoa1412082 |
|
2015 Journal Article Radiotherapy utilization in the BRAF-mutation test metastatic melanoma in the targetted therapy era.Gorayski, Peter, Dzienis, Marcin, Foote, Matthew, Atkinson, Victoria, Burmeister, Elizabeth and Burmeister, Bryan (2015). Radiotherapy utilization in the BRAF-mutation test metastatic melanoma in the targetted therapy era.. Asia Pacific Journal of Oncology, 13 (2), E117-E123. doi: 10.1111/ajco.12345 |
|
2015 Conference Publication Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapyPrivthviraj, Prashanth, McArthur, Grant, Atkinson, Victoria, Parente, Phillip, Andrews, Miles Cameron, Parakh, Sagun, Cebon, Jonathon and Klein, Oliver (2015). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy. American Society of Clinical Oncology Annual Meeting, 2015, Chicag, Il United States, 29 May - 2 June 2015. Alexandria, VA United States: American Society of Clinical Oncology. |
|
2014 Journal Article Combined Vemurafenib and Combimetinib in BRAF-Mutated MelanomaLarkin, James, Ascierto, Paolo, Dren, Brigette, Atkinson, Victoria, Liszkay, Gabriella, Maio, Michele, Mandala, Mario, Demidov, Lev, Stroyakovskiy, Daniil, Thomas, Luc, de la Cruz-Merino, Luis, Dutriaux, Caroline, Garbe, Claus, Sovak, Mika, Chang, Ilsung, Choong, Nicholas, Hack, Stephen, McArthur, Grant A. and Ribas, Antoni (2014). Combined Vemurafenib and Combimetinib in BRAF-Mutated Melanoma. The New England Journal of Medicine, 371 (20), 1867-1876. doi: 10.1056/NEJMoa1408868 |
|
2014 Journal Article BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy with or without TrametinibMcClenahan, Phil, Lin, Lynlee L., Tan, Jean-Marie, Flewell-Smith, Ross, Schaider, Helmut, Jagirdar, Kasturee, Atkinson, Victoria, Lambie, Duncan, Prow, Tarl W., Sturm, Richard A. and Soyer, Peter (2014). BRAFV600E Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy with or without Trametinib. JAMA Dermatology, 150 (10), 1079-1082. doi: 10.1001/jamadermatol.2014.436 |
|
2014 Conference Publication Safety and Efficacy Analysis of Patients From the Dabrafenib Named Patient Programme in Patients with V600 BRAF-Mutated Metastatic Melanoma – DESCRIBE StudyMartin-Algarra, Salvador, Cebon, Jonathan, Neyns, Bart, Brown, Ewan, Puertolas, Teresa, Garcia, Yolanda, Atkinson, Victoria, Crown, John, Lau, Mike, Dalland, Lindi, Stein, Dara, Payne, Krista, Aktan, Gursel, Jobanputra, Minesh, Queirolo, Paola and Millward, Michael (2014). Safety and Efficacy Analysis of Patients From the Dabrafenib Named Patient Programme in Patients with V600 BRAF-Mutated Metastatic Melanoma – DESCRIBE Study. Society for Melanoma Research, Zurich, Switzerland, November 2014. Hoboken, NJ United States: Wiley-Blackwell Publishing. doi: 10.1111/pcmr.12317 |
|
2014 Journal Article Response rate to Vemurafenib in patients with B-RAF positive melanoma brain metastasis: a retrospective reviewDzienis, Marcin and Atkinson, Victoria (2014). Response rate to Vemurafenib in patients with B-RAF positive melanoma brain metastasis: a retrospective review. Melanoma Research, 24 (4), 349-353. doi: 10.1097/CMR.0000000000000068 |
|
2013 Conference Publication Response rate to Vemurafenib in BRAF-positive melanoma brain metastases2013Dzienis, Marcin Radoslaw and Atkinson, Victoria (2013). Response rate to Vemurafenib in BRAF-positive melanoma brain metastases2013. American Society of Clinical Oncology Annual Meeting, 2013, Chicago, IL United States, 31 May - 3 June 2013. Alexandria, VA United States: American Society of Clinical Oncology. |
|
2013 Conference Publication Single institution experience of Hyperthermic Intraperitoneal ChemotherapyXu, Wen, Sparks, David, Atkinson, Victoria, Joubert, Warren, Lutton, Nicholas and Meade, Brian (2013). Single institution experience of Hyperthermic Intraperitoneal Chemotherapy. Annual Scientific Meeting of Medical Oncology Group of Australia, Melbourme, Australia, August 2013. |
|
2012 Conference Publication Retrospective review of patients managed with chemotherapy for metastatic colorectal cancer at the Princess Alexandra HospitalRyan, C., Atkinson, V. and Klein, K. (2012). Retrospective review of patients managed with chemotherapy for metastatic colorectal cancer at the Princess Alexandra Hospital. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting: Targeting Cancer from Diagnosis to Cure & 5th Annual COGNO Annual Scientific Meeting, Queensland, Australia, 8 – 10 August 2012. Oxford, United Kingdom: Wiley-Blackwell Publishing. |
|
2011 Conference Publication Single Institution Experience of the Stupp Protocol in Management of Glioblastoma MultiformeCaird, Susan and Atkinson, Victoria (2011). Single Institution Experience of the Stupp Protocol in Management of Glioblastoma Multiforme. Annual Scientific Meeting of Medical Oncology Group of Australia, Adelaide, SA Australia, 10-12 August 2011. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/j.1743-7563.2011.01417.x |
